Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

286999

Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

Combining Erleada (apalutamide) and Zytiga (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC) significantly extends the time patients live without signs of disease worsening, compared with Zytiga alone, Janssen announced in a press release. Findings from the ACIS Phase 3 trial (NCT02257736), which enrolled patients on androgen deprivation therapy (ADT) who had not been treated with chemotherapy, also showed that the combination led to stronger responses and a trend toward better overall survival. Trial’s findings were…

You must be logged in to read/download the full post.